{"id":251451,"date":"2021-10-06T00:00:00","date_gmt":"2021-10-06T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/epidid0016-biopharma-clostridium-difficile-infection-epidemiology-2\/"},"modified":"2026-04-21T11:23:09","modified_gmt":"2026-04-21T11:23:09","slug":"epidid0016-biopharma-clostridium-difficile-infection-epidemiology-mature-markets","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidid0016-biopharma-clostridium-difficile-infection-epidemiology-mature-markets\/","title":{"rendered":"Clostridium Difficile Infection &#8211; Epidemiology &#8211; Mature Markets"},"content":{"rendered":"<p>Clarivate Epidemiology\u2019s coverage of <em>clostridium difficile<\/em> infection (<abbr data-abbreviation-entity=\"6710\" title=\"Clostridium difficile infection\">CDI)<\/abbr> comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report both the incidence and prevalence of <abbr title=\"Clostridium difficile infection\">CDI<\/abbr> for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>In addition to forecasting incident and prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy.<\/p>\n<p>Clarivate Epidemiology\u2019s <abbr title=\"Clostridium difficile infection\">CDI<\/abbr> forecast will answer the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>Of all people diagnosed with <abbr title=\"Clostridium difficile infection\">CDI<\/abbr>, how many in each of the major mature pharmaceutical markets are drug-treated?<\/li>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr title=\"Clostridium difficile infection\">CDI<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>In total, Clarivate Epidemiology forecasts 48 <abbr title=\"Clostridium difficile infection\">CDI<\/abbr> patient populations, including the following:<\/p>\n<ul class=\"round-bullets\">\n<li>Diagnosed hospital treated events of C. difficile infection.<\/li>\n<li>Diagnosed hospital treated events of recurrent C. difficile infection.<\/li>\n<li>Diagnosed hospital treated events of severe C. difficile infection.<\/li>\n<li>Diagnosed hospital treated events of healthcare-associated C. difficile infection.<\/li>\n<li>Diagnosed hospital treated events of hospital-onset C. difficile infection.<\/li>\n<li>Diagnosed hospital treated events of community-onset, healthcare-associated C. difficile infection.<\/li>\n<li>Diagnosed hospital treated events of nursing home-onset C. difficile infection.<\/li>\n<li>Diagnosed hospital treated events of community-associated C. difficile infection.<\/li>\n<li>Diagnosed hospital treated events of C. difficile infection with comorbidities.<\/li>\n<li>Diagnosed hospital treated events of drug-treated C. difficile infection.<\/li>\n<\/ul>\n<p>Note: Coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-251451","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-clostridium-difficile-infection","biopharma-therapy-areas-clostridium-difficile-infections","biopharma-product-epidemiology","biopharma-date-950"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251451","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251451\/revisions"}],"predecessor-version":[{"id":283886,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251451\/revisions\/283886"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=251451"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}